Evidence map›Paper›PMID 24045499›Full record

ArticleLeukemia2014

DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.

W S Stevenson, O G Best, A Przybylla, Q Chen, N Singh, M Koleth, S Pierce, T Kennedy, W Tong, S-Q Kuang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Targeting PRL phosphatases in hematological malignancies.Expert opinion on therapeutic targets · 2024
    Review
  3. Article
  4. PTPRO-related CD8Frontiers in immunology · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

W S Stevenson1] Department of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia [2] Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
O G BestNorthern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
A PrzybyllaNorthern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
Q Chen1] Department of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia [2] Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
N SinghDepartment of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia.
M KolethDepartment of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia.
S PierceDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
T KennedyDepartment of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia.
W TongDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
S-Q KuangDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
G Garcia-ManeroDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USNorth Shore Hospital · NZRoyal North Shore Hospital · AUThe University of Sydney · AU

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

Aberrant DNA promoter methylation with associated gene silencing is a common epigenetic abnormality in acute lymphoblastic leukaemia (ALL) and is associated with poor survival. We have identified a family of transmembrane tyrosine phosphatase proteins as targets of hypermethylation in ALL and high-grade B cell lymphoma and demonstrated that this abnormal methylation correlates with transcript expression. PTPRG was methylated in 63% of ALL samples, PTPRK in 47%, PTPRM in 64% and PTPRO in 54% of cases, with most ALL samples containing methylation at multiple phosphatase loci. PTPRK promoter methylation was associated with a decreased overall survival in the cohort. Restoration of PTPRK transcript levels in leukaemia cells, where phosphatase transcript was silenced, reduced cell proliferation, inhibited colony formation and increased sensitivity to cytotoxic chemotherapy. These biological changes were associated with a reduction in levels of phosphorylated Erk1/2, Akt, STAT3 and STAT5 suggesting functional phosphatase activity after transcript re-expression. Methylation of the phosphatase promoters was reversible with decitabine and a histone deacetylase inhibitor, suggesting that PTPRK-mediated cell signalling pathways may be targeted with epigenetic therapies in lymphoid malignancy.

Indexed as

DNA MethylationAdolescentAdultAgedCell Line, TumorCell ProliferationCpG IslandsHumansJanus Kinase 1Middle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPromoter Regions, GeneticProportional Hazards ModelsProtein Tyrosine PhosphatasesReceptor-Like Protein Tyrosine Phosphatases, Class 2STAT3 Transcription FactorJAK1 protein, humanJanus Kinase 1Protein Tyrosine PhosphatasesPTPRK protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 2STAT3 protein, humanSTAT3 Transcription FactorSTAT5 Transcription Factor

Identifiers

PMID24045499
OpenAlexW1993788262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.